Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma

Q. Lee, E.; A. Reardon, David; Schiff, D.; Drappatz, J.; Muzikansky, Alona; Grimm, Sean; D. Norden, Andrew; Nayak, Lakshmi; Beroukhim, Rameen; L. Rinne, Mikael; S., A.; T. Batchelor, Tracy; Hempfling, K.; McCluskey, Christine; H. Smith, Katrina; Gaffey, Sarah; Wrigley, Brendan; L. Ligon, Keith; J. Raizer, Jeffrey; Y Wen, Patrick

doi:10.1093/neuonc/nou350

Public

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma

Published in Neuro-Oncology • Jan 7, 2015

Authors:

E. Q. Lee

David A. Reardon

D. Schiff

Abstract

BACKGROUND: Panobinostat is a histone deacetylase inhibitor with antineoplastic and antiangiogenic effects in glioma that may work synergistically with bevacizumab. We conducted a multicenter phase II trial of panobinostat combined with bevacizumab in patients with recurrent high-grade glioma (HGG)....

Subject

Panobinostat

Bevacizumab

Glioma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!